The HZI will develop a vaccination protocol for mucosal
administration based on three novel strategies: (i) development and optimization of a vaccination protocol in which parenterally - primed T and B cells are subsequently pulled into the mucosa by the local delivery of the cognate antigen to the requested effector site, (ii) testing the co-
administration of antigens with novel mucosal adjuvants using different mucosal immunisation routes and schedules, and (iii) testing various nanoparticles co-administered with different immunomodulators for their ability to generate both
systemic and mucosal immune responses
following transcutaneous / trans - follicular vaccination.
This protocol is a dose escalation study of Ad - hCMV - TK and Ad - hCMV - Flt3L infused at the time of surgical resection
followed by
systemic oral
administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy.